O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial

医学 内科学 肿瘤科 临床试验 随机对照试验 梅德林 放射治疗 胶质母细胞瘤 外科 疾病 癌症 生活质量(医疗保健)
作者
Anca‐Ligia Grosu,Wolfgang Weber,Erika Graf,Michael D. Mix,Ursula Nestle,Tanja Schimek‐Jasch,R. Wiehle,Irina Mader,Urs Würtemberger,Karl‐Josef Langen,Maximilian Niyazi,Frank Paulsen,Liane König,Frank Anton Giordano,Irina Spehl,Denise Bernhardt,Markus Michael Schymalla,Christoph Pöttgen,Sabine Semrau,Thomas Brunner
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:27 (2): 169-180 被引量:19
标识
DOI:10.1016/s1470-2045(25)00642-4
摘要

BACKGROUND: F]fluoroethyl)-L-tyrosine (FET)-PET has a higher specificity than contrast-enhanced T1-weighted MRI (CE-T1MRI) in diagnosing recurrent glioblastoma. We aimed to evaluate whether a FET-PET-based target volume delineation, compared with CE-T1MRI, improves outcomes in patients with recurrent glioblastoma scheduled for re-irradiation. METHODS: GLIAA was a multicentre, open-label, parallel randomised study done in 15 radiation oncology centres in Germany. Patients aged 18 years or older with a Karnofsky performance score greater than 60% and a macroscopic WHO grade IV recurrent glioblastoma (1-6 cm) were randomly assigned (1:1) to receive either FET-PET-based or CE-T1MRI-based target volume delineation followed by re-irradiation with 39 Gy in 13 fractions. Randomisation was performed centrally, using a minimisation technique with a random element and a computer-assisted randomisation tool, stratified by time since first radiotherapy, previous chemotherapy, tumour diameter, MGMT status, and planned chemotherapy. The primary endpoint was progression-free survival from randomisation, assessed in the per-protocol population (patients who initiated treatment per their assigned group). Adverse events were systematically assessed in all patients who commenced therapy. The trial was registered with ClinicalTrials.gov (NCT01252459), German Clinical Trials Registry (DRKS00000634), and European Clinical Trials Database (EudraCT 2012-001121-27), and is completed. FINDINGS: Between Nov 22, 2013, and Aug 18, 2021, 271 patients were recruited and screened for eligibility, 200 of whom were randomly assigned to re-irradiation based on FET-PET (n=100) or CE-T1MRI (n=100). 85 (43%) participants were female and 115 (58%) were male. 98 patients in the FET-PET group and 97 in the CE-T1MRI group were treated per protocol. Median follow-up for censored patients was 12·2 months (IQR 6·6-20·7). Median progression-free survival was 4·0 months (95% CI 3·7-5·2) in the FET-PET group and 4·9 months (3·7-6·0) in the CE-T1MRI group (one-sided stratified log-rank p=0·98; adjusted hazard ratio 1·14 [95% CI 0·85-1·52]; p=0·39; median follow-up for six censored patients 4·1 months [IQR 2·3-6·6]). The most common grade 3-4 adverse event was radionecrosis (eight [8%] of 99 in the FET-PET group vs seven [7%] of 99 in the CE-T1MRI group). Acute and subacute serious adverse events occurred in 15 (15%) of 99 patients in each group; possibly re-irradiation-related late serious adverse events occurred in ten (10%) of 97 patients in the FET-PET group and 18 (19%) of 96 in the CE-T1MRI group. There were no treatment-related deaths. INTERPRETATION: FET-PET-based target volume delineation for re-irradiation did not lead to a significant clinical benefit compared with CE-T1MRI-based treatment in patients with recurrent glioblastoma. Thus, CE-T1MRI remains the preferred delineation method in this setting. FUNDING: Deutsche Krebshilfe.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
乐乐乐发布了新的文献求助10
1秒前
斯文败类的应助被赵彬旭采纳,获得10
2秒前
充电宝的应助被猇会不会采纳,获得10
2秒前
傢誠发布了新的文献求助10
2秒前
耿春丽发布了新的文献求助10
3秒前
chiaoyin999发布了新的文献求助10
3秒前
3秒前
syvshc的应助被hansang采纳,获得10
3秒前
柠栀完成签到,获得积分10
3秒前
落俗完成签到,获得积分10
3秒前
3秒前
4秒前
无花果的应助被Yu采纳,获得10
5秒前
Voyager发布了新的文献求助10
5秒前
17826539164发布了新的文献求助10
5秒前
5秒前
苏苏苏发布了新的文献求助10
5秒前
华仔的应助被称心的蛟凤采纳,获得10
6秒前
gwgplmz完成签到,获得积分10
6秒前
LuckyYu发布了新的文献求助10
6秒前
小栩发布了新的文献求助10
6秒前
学术智子发布了新的文献求助10
7秒前
小蘑菇的应助被Drcai采纳,获得10
7秒前
8秒前
Maestro_S的应助被ddw采纳,获得150
8秒前
9秒前
希芜完成签到 ,获得积分10
9秒前
10秒前
WWL完成签到,获得积分10
10秒前
初景发布了新的文献求助10
11秒前
Samming发布了新的文献求助10
11秒前
留胡子的寄瑶完成签到,获得积分10
12秒前
1101592875的应助被psl采纳,获得10
13秒前
sc发布了新的文献求助10
13秒前
栀子完成签到 ,获得积分10
13秒前
沥练的应助被DD采纳,获得10
13秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187612
求助须知:如何正确求助?哪些是违规求助? 9575734
关于积分的说明 21842594
捐赠科研通 7785476
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559478
邀请新用户注册赠送积分活动 2481952